In conclusion, the current results show that calycosin has pharmacological effects against osteosarcoma (OS) by both in vivo and in vitro inhibiting the neoplastic IκBa/ECT2 pathway and suppressing the neoplastic miR‐223‐IκBα pathway, both of which are connected to triggering death in tumor cells. Here, ECT2 is linked to osteosarcoma.